Covidien (UNKNOWN:COV.DL) and Medtronic (NYSE:MDT) announced a tie-up over the weekend for $42.9 billion, and Covidien promptly shot up over 20% today on investor optimism around the deal. And with Medtronic offering a 29% premium to last Friday's close and both boards of directors behind the proposal, there appears to be much reason for optimism about the deal going through.

But we're long-term investors, so the big question for us is also the simplest: Does this acquisition make sense?

In the video below, from Market Checkup, the Motley Fool's health care-focused investing show, health care analysts Michael Douglass and David Williamson give their answer.

David Williamson owns shares of Pfizer. Michael Douglass has no position in any stocks mentioned. The Motley Fool recommends Covidien and Valeant Pharmaceuticals. The Motley Fool owns shares of Medtronic and Valeant Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.